Diagnosis and therapy of ulcerative colitis: Extraintestinal manifestations in ulcerative colitis;Diagnostik und theraoie der colitis ulcerosa: Extraintestinale manifestationen bei colitis ulcerosa

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 9, 2004, Pages 1024-1028

  Reinshagen, M ^a   Folsch U R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIUM; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; URSODEOXYCHOLIC ACID; VITAMIN D;

ANKYLOSING SPONDYLITIS; APHERESIS; ARTHRALGIA; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; CLINICAL FEATURE; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; PYODERMA GANGRENOSUM; ULCERATIVE COLITIS; ARTHRITIS; ARTICLE; DIFFERENTIAL DIAGNOSIS; EYE DISEASE; RISK FACTOR; SCLEROSING CHOLANGITIS; SKIN DISEASE;

ARTHRITIS; CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; DIAGNOSIS, DIFFERENTIAL; EYE DISEASES; HUMANS; OSTEOPOROSIS; RISK FACTORS; SKIN DISEASES;

EID: 10344262105     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813492     Document Type: Conference Paper

References (55)

1. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-391 (IIb)
2. Bernstein CN, Blanchard JF, Rawsthorne P et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-1122 (IIb)
3. Scarpa R, del Puente A, D'Arienzo A et al. The arthritis of ulcerative colitis: clinical and genetic aspects. J Rheumatol 1992; 19: 373-377 (IIb)
4. de Vlam K, Mielants H, Cuvelier C et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27: 2860-2865 (IIb)
5. Palm O, Moum B, Jahnsen J et al. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) 2001; 40: 1256-1261 (IIb)
6. Jones G, Halbert J, Crotty M et al. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford) 2003; 42: 6-13 (Ia)
7. Freitas J, Farricha V, Nascimento I et al. Rofecoxib: a possible cause of acute colitis. J Clin Gastroenterol 2002; 34: 451-453 (IV)
8. Van Den Bosch F, Kruithof E, Baeten D et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755-765 (Ib)
9. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193 (Ib)
10. Thomas PD, Keat AC, Forbes A et al. Extraintestinal manifestations of ulcerative colitis following restorative proctocolectomy. Eur J Gastroenterol Hepatol 1999; 11: 1001-1005 (IIa)
11. Teixeira WG, da Silva JH, Teixeira MG et al. Pouchitis: extracolonic manifestation of ulcerative colitis? Rev Hosp Clin Fac Med Sao Paulo 1999; 54: 155-158 (III)
12. Lohmuller JL, Pemberton JH, Dozois RR et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouchanal anastomosis. Ann Surg 1990; 211: 622-627; discussion 627-629 (III)
13. Olsson R, Danielsson A, Jarnerot G et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-1323 (IIb)
14. Parlak E, Kosar Y, Ulker A et al. Primary sclerosing cholangitis in patients with inflammatory bowel disease in Turkey. J Clin Gastroenterol 2001; 33: 299-301 (III)
15. Christodoulou DK, Katsanos KH, Kitsanou M et al. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig Liver Dis 2002; 34: 781-786 (III)
16. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000; 33: 537-542 (III)
17. Boberg KM, Fausa O, Haaland T et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996; 23: 1369-1376 (III)
18. van Buuren HR, van Hoogstraten HJE, Terkivatan T et al. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000; 33: 543-548 (III)
19. Weber C, Krupski G, Lorenzen J et al. MRCP in primary sclerosing cholangitis. Fortschr Röntgenstr 2003
20. Textor HJ, Flacke S, Pauleit D et al. Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 2002: 34: 984-990 (III)
21. Ferrara C, Valeri G, Salvolini L et al. Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children. Pediatr Radiol 2002; 32: 413-417 (IIb)
22. Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003; 98: 1155-1158 (IIb)
23. Beuers U, Spengler U, Kruis W et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16: 707-714 (Ib)
24. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695 (Ib)
25. Harnois DM, Angulo P, Jorgensen RA et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 1558-1562 (Ib)
26. Mitchell SA, Bansi DS, Hunt N et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 900-907 (Ib)
27. Baluyut AR, Sherman S, Lehman GA et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001; 53: 308-312 (IIb)
28. Stiehl A, Rudolph G, Kloters-Plachky P et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36: 151-156 (IIb)
29. Tung BY, Emond MJ, Haggitt RC et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95 (IIb)
30. Pardi DS, Loftus EV Jr, Kremers WK et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-893 (III)
31. Boberg KM, Bergquist A, Mitchell S et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002: 37: 1205-1211 (III)
32. Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 1992; 26: 371-383 (III)
33. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine. (Baltimore), 1976: 55: 401-412 (III)
34. Tromm A, May D, Almus E et al. Hautmanifestationen bei chronisch entzündlichen Darmerkrankungen. Z Gastroenterol 2001; 39: 137-144 (III)
35. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23: 29-34 (III)
36. Regueiro M, Valentine J, Plevy S et al. Infliximab for treatment of pyoderma gangraenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821-1826 (IV)
37. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangraenosum. Jama 2000; 284: 1546-1548 (IV)
38. Menachem Y, Gotsman I. Clinical manifestations of pyoderma gangraenosum associated with inflammatory bowel disease. Isr Med Assoc J 2004; 6: 88-90 (III)
39. Latkany PA, Jabs DA. Ocular manifestations of inflammatory bowel disease. In: Bayless TM, Hanauer SB. Advanced therapy of inflammatory bowel disease. London: B.C. Decker, 2001; 275-277 (III)
40. Soukiasian SH, Foster CS, Raizman MB. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol 1994; 118: 601-611 (III)
41. de Vries J, Baarsma GS, Zaal MJ et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 1990; 74: 344-349 (Ib)
42. Joseph A, Raj D, Dua HS et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003; 110: 1449-1453 (IIb)
43. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 795-841 (Ia)
44. Ghosh S, Cowen S, Hannan WJ et al. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107: 1031-1039 (IIb)
45. Reffitt DM, Meenan J, Sanderson JD et al. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003; 15: 1267-1273 (IIb)
46. Bernstein CN, Blanchard JF, Leslie W et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000: 133: 795-799 (IIb)
47. van Staa TP, Cooper C, Brusse LS et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003; 125: 1591-1597 (IIb)
48. Vestergaard P, Krogh K, Rejnmark L et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46: 176-181 (IIa)
49. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Bmj 1996; 312: 1254-1259 (Ia)
50. Andreassen H, Rungby J, Dahlerup JF et al. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997: 32: 1247-1255 (IV)
51. Vogelsang H, Klamert M, Resch H et al. Dietary vitamin D intake in patients with Crohn's disease. Wien Klin Wochenschr 1995; 107: 578-581 (IIb)
52. Bernstein CN, Seeger LL, Anton PA et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10: 777-786 (Ib)
53. Adachi JD, Ioannidis G. Calcium and vitamin D therapy in corticosteroid-induced bone loss: what is the evidence? Calcif Tissue Int 1999; 65: 332-336 (Ia)
54. Buckley LM, Leib ES, Cartularo KS et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 961-968 (Ib)
55. Adler G, Reinshagen M. Extraintestinale Manifestationen. Z Gastroenterol 2003; 41: 54-61 (IV)